Title:
A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Phase:
III
Contact:
Jennifer Klemmer / Kontaktperson
Email-Address:
Jennifer.Klemmer@med.uni-heidelberg.de
Clinical Investigator:
Dr. med. Tim Sauer
Registration:
Keine Registernummer angegeben.
EudraCT-Number:
Siehe EU klinisches Studienregister
2022-000995-21